Autoregulation of inducible nitric oxide synthase expression by RNA interference provides neuroprotection in neonatal rats

Theranostics. 2015 Feb 15;5(5):504-14. doi: 10.7150/thno.10441. eCollection 2015.

Abstract

We have shown that autoregulation of gene expression by RNA interference is achievable in cell cultures. To determine whether this novel concept could be used to produce neuroprotection under in vivo condition, postnatal day (PND) 3 rats received intracerebroventricular injection of lentivirus that carried or did not carry code for short hairpin RNA (shRNA) of inducible nitric oxide synthase (iNOS). The expression of this shRNA was controlled by an iNOS promoter (piNOS-shRNA) or cytomegalovirus promoter (pCMV-shRNA). The rats were subjected to brain hypoxia-ischemia at PND7. Ischemic brain tissues had increased iNOS expression. This increase was attenuated by virus carrying piNOS-shRNA. Virus carrying pCMV-shRNA reduced iNOS to a level that was lower than control. Brain tissue loss and functional impairment after the hypoxia-ischemia were attenuated by the virus carrying piNOS-shRNA but not by pCMV-shRNA. Our results provide proof-of-concept evidence that autoregulation of iNOS expression by RNA interference induces neuroprotection in vivo and that appropriate regulation of gene expression is important.

Keywords: autoregulation of gene expression; inducible nitric oxide synthase; neonate; neuroprotection; rats..

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Female
  • Gene Expression Regulation / drug effects*
  • Hypoxia, Brain / prevention & control*
  • Hypoxia-Ischemia, Brain / complications*
  • Male
  • Neuroprotective Agents / administration & dosage*
  • Nitric Oxide Synthase Type II / biosynthesis*
  • Nitric Oxide Synthase Type II / genetics
  • RNA Interference*
  • RNA, Small Interfering / administration & dosage*
  • Rats, Sprague-Dawley
  • Treatment Outcome

Substances

  • Neuroprotective Agents
  • RNA, Small Interfering
  • Nitric Oxide Synthase Type II